ClinicalTrials.gg
CompletedNCT06672276Updated Jan 9, 2026

To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency

A Phase 1 interventional study of TQD3606 in Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is an open, parallel, single-dose phase I clinical study to evaluate the pharmacokinetics and safety of TQD3606 for injection in subjects with renal insufficiency.

02

Conditions studied

  • Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects are required to meet all of the following criteria for inclusion in this study:

  • Understand the content, process and possible adverse reactions of the trial, be able to complete the study in accordance with the requirements of the trial protocol, and voluntarily sign the ;
  • Participants (including their partners) voluntarily used effective within 3 months from 2 weeks before until the last use of study drug;
  • Participants aged 18 \~ 75 ;
  • (BMI) and 18 or 32 kg/m2 or less, and the male weight 50 kg or greater, female weight 45 kg or more;

For renal impairment subjects, also required meet all of the following criteria for inclusion in this study:

  • Subjects with moderate to severe renal insufficiency and end-stage renal disease were required to meet the diagnostic criteria for chronic kidney disease(CKD);
  • Stable renal function: creatinine detection of at least two intervals of 3 days (30 days before the screening test results for the first time acceptable) inside and outside school or in our test result, and two detecting serum creatinine results before and after the fluctuation (calculation formula: (second results - 1)) / 1 time is less than 30%;
  • During the screening period, the individual (GFR, mL/min, using the modification of diet in renal disease( MDRD) formula, based on the results of the second serum creatinine test) was classified as follows: 60≤GFR≤89 mL/min (Group A, mild renal dysfunction, CKD2 period), or 30≤GFR≤59 mL/min (Group B, moderate renal dysfunction, CKD3 period), or 15≤GFR≤29 mL/min (Group C, severe renal dysfunction, CKD4 period).

Subjects in the normal renal function group must also meet the following criteria for inclusion in this study:

  • Those who have normal results of laboratory examination, physical examination, 12-lead (ECG), anterolateral chest x-ray and color ultrasound during the screening period, or those who are judged to be abnormal and non- by the investigator;
  • Individual glomerular filtration rate (GFR, mL/min, MDRD formula) during the screening period of subjects: GFR≥90 mL/min;

Exclusion criteria

Exclusion Criteria:

All subjects were not eligible for the study if they met any of the following criteria:

  • Those with allergies, or known history of allergy to meropenem or avibactam, known history of anaphylactic shock or other severe allergic reactions to penicillins, cephalosporins, carbapenems and other β-lactam antibiotics (such as epidermolysis bullosa atrophic dermatitis, exfoliative dermatitis), etc.;
  • Those who have any type of treated or untreated malignant tumor (whether cured or not) within 5 years before screening or in the baseline period (except for basal cell carcinoma of the skin);
  • Those who have serious digestive system, respiratory system, nervous system, blood system, endocrine system, tumor, immune, psychiatric or cardiovascular and cerebrovascular diseases within 1 year before screening, and are not suitable to participate in this trial as assessed by the investigator;
  • Those who have major diseases or major surgeries within 4 weeks before dosing, or those who plan to undergo surgery during the study;
  • Those who have donated (or lost blood) ≥ 400 mL within 3 months before screening, or have received blood products;
  • Those who smoke more than 10 cigarettes per day on average in the 3 months before screening;
  • History of substance abuse within 5 years prior to screening, and/or average weekly alcohol intake of more than 14 units (female subjects) or 21 units (male subjects) in the 3 months prior to screening (1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
  • Those who have taken a special diet (including dragon fruit, mango, grapefruit, and/or xanthine diet, chocolate) and/or excessive consumption of tea, coffee, grapefruit/grapefruit juice and/or caffeinated beverages (an average of more than 8 cups per day, each cup of 200 mL) within 2 weeks before dosing;
  • Those who have ingested any products containing alcohol within 48 hours before receiving the study drug, or those who have a positive alcohol breath test;
  • Drug abusers, or those who have used soft drugs (such as marijuana) within 3 months before screening, or who have taken hard drugs within 1 year before screening, or who have a positive urine drug screen at baseline;
  • Active virus (HBV) () or virus (HCV) infection, or (HIV) antibody positive; or those who are positive for treponema pallidum antibodies ;
  • Female subjects are lactating during the screening period or during the trial or have a positive serum pregnancy result;
  • Other situations that the investigator considers unsuitable for enrollment.

Renal impairment subjects were not eligible for the study if they met any of the following criteria:

  • Those who have participated in other clinical studies within 1 month before screening and have used any clinical investigation drugs or medical devices, the date of the last clinical study administration shall be used as the time benchmark (if it is a clinical investigation drug with a long half-life, at least 5 half-lives should be separated from the administration of this study);
  • Patients with acute renal failure, with a history of kidney transplantation, or subjects who require kidney transplantation or undergo any type of dialysis during the expected trial;
  • Obstructive urinary tract disease (e.g., urinary tract obstruction caused by urinary stones, urinary tract obstruction caused by abdominal mass lesions, etc.) or causes of renal impairment unrelated to renal parenchymal dysfunction (e.g., polycystic kidney, renal tumor, renal artery stenosis, drugs, severe infection, volume depletion, heart failure, etc.);
  • People with urinary incontinence;
  • At the time of screening, the therapeutic drugs and/or other treatment drugs for comorbidities have not met the requirements of stable medication for 1 month, or there are new drugs within 1 month (except for drugs used temporarily or intermittently, such as erythropoietin used once a month, or diuretics are temporarily required, etc.);
  • Systolic blood pressure ≥ 160 mmHg or ≤80 mmHg, diastolic blood pressure ≥ 100 mmHg or ≤50 mmHg, and heart rate outside the range of 50-100 beats/minute (both ends inclusive) during the screening period or baseline period;
  • (ALT) or aspartate aminotransferase (AST) > 2× (upper limit of normal, ULN) and total > 1.5×ULN in the screening period or baseline period; albumin\< 25 g/L; Absolute neutrophil value\< 1.3×109/L; \< 80g/L; count\< 80×109/L;
  • Congestive heart failure with (NYHA) grade III or IV, or \<50% at screening;

Normal subjects were excluded from the study if they met any of the following criteria:

  • Those who have participated in other clinical studies within 3 months before screening and have used any clinical investigation drugs or medical devices, with the date of the last clinical study administration as the time benchmark (if it is a clinical investigation drug with a long half-life, there needs to be at least 5 half-lives between it and the administration of this study);
  • Those who have used any drug within 14 days or 5 half-lives (whichever is longer) before dosing.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    A: Subjects with mild renal insufficiency

    This group patients were given TQD3606 only one time

    Drug: TQD3606

  • Active comparator
    B: Subjects with moderate renal insufficiency

    This group patients were given TQD3606 only one time

    Drug: TQD3606

  • Active comparator
    C: Subjects with severe renal insufficiency

    This group patients were given TQD3606 only one time

    Drug: TQD3606

  • Active comparator
    D: Health volunteers

    This group patients were given TQD3606 only one time

    Drug: TQD3606

Interventions

  • DrugTQD3606

    TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Peak blood drug concentration of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  2. Area under the concentration-time curve (AUC)

    The area under the time curve of the plasma concentration -time curve of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  3. Time-to-maximum concentration (Tmax)

    Time-to-maximum concentration of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  4. Total body clearance (CLt)

    Total body clearance of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  5. Renal clearance (CLr)

    Renal clearance of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  6. Apparent volume of distribution (Vd/F)

    Volume of distribution based on the terminal phase of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  7. Terminal elimination rate (λz)

    First-order rate constant associated with the terminal (log-linear) elimination phase of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

  8. Mean residence time (MRT)

    The average time that the drug stays in the body of meropenem and avibactam.

    Time frame: Before administration, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours after administration

Secondary outcomes

  1. Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)

    Ae0-24 of meropenem and avibactam.

    Time frame: 0h before administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours after administration

  2. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

    Time frame: Baseline up to 72 hours

07

Study locations

2 sites
  • The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
    Jinan, Shandong 250014, China
  • The Second Hospital of Shandong University
    Jinan, Shandong 250014, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in May 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 4, 2024
StartActual
Nov 20, 2024
Primary completionActual
May 6, 2025
CompletionActual
May 6, 2025
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06672276
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Nov 20, 2024
Primary completion
May 6, 2025
Completion
May 6, 2025
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion